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Abstract
Background: MicroRNAs (miRNAs) are short single stranded noncoding RNAs that suppress gene expression through either
translational repression or degradation of target mRNAs. The annealing between messenger RNAs and 59 seed region of
miRNAs is believed to be essential for the specific suppression of target gene expression. One miRNA can have several
hundred different targets in a cell. Rapidly accumulating evidence suggests that many miRNAs are involved in cell cycle
regulation and consequentially play critical roles in carcinogenesis.
Methodology/Principal Findings: Introduction of synthetic miR-107 or miR-185 suppressed growth of the human non-
small cell lung cancer cell lines. Flow cytometry analysis revealed these miRNAs induce a G1 cell cycle arrest in H1299 cells
and the suppression of cell cycle progression is stronger than that by Let-7 miRNA. By the gene expression analyses with
oligonucleotide microarrays, we find hundreds of genes are affected by transfection of these miRNAs. Using miRNA-target
prediction analyses and the array data, we listed up a set of likely targets of miR-107 and miR-185 for G1 cell cycle arrest and
validate a subset of them using real-time RT-PCR and immunoblotting for CDK6.
Conclusions/Significance: We identified new cell cycle regulating miRNAs, miR-107 and miR-185, localized in frequently
altered chromosomal regions in human lung cancers. Especially for miR-107, a large number of down-regulated genes are
annotated with the gene ontology term ‘cell cycle’. Our results suggest that these miRNAs may contribute to regulate cell
cycle in human malignant tumors.
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Introduction
miRNAs are 19 to 23-base long single stranded RNAs that play
critical roles in biological processes [1]. The nucleotide sequences
of miRNAs are often evolutionally conserved among multicellular
organisms [2]. The miRNAs are expressed as hairpin shaped
double stranded pre-miRNAs and sequential processing by
different RNase III enzymes, Drosha and Dicer, generates mature
miRNA [3].The mature miRNA binds with a set of proteins,
including Agonaute, to form a miRNA induced silencing complex
(miRISC). The miRISC is believed to make a complex with target
messenger RNAs and post-transcriptionally suppresses the expres-
sion of the target genes. The mechanism of action of miRISC is
still controversial [4], however, there is a general consensus that
majority of target messenger RNAs have binding sites for the
miRNAs in the 39 untranslated regions. From second to eighth
bases of 59 end sequence of miRNA is called seed sequence and is
believed to be essential for the recognition of the target messenger
RNAs by miRNAs.
It has become evident that some miRNAs play critical roles in
the cell cycle regulation in cooperation with the oncogenes or
tumor suppressor genes (see review [5,6]). One example of cell
cycle regulating miRNA is the let-7(for hsa-let-7a, MI-
MAT0000062). The introduction of synthetic pre-let-7 causes
the cell cycle arrest in lung cancer cells [7]. Many miRNAs are
known to downregulate cell cycle related genes. The miR-17,92
cluster was identified as the downstream of the MYC oncogene [8]
and downregulate E2F transcription factors which are well-known
mediators of cell cycle progression [9].Another important tumor
related gene, the TP53, induce the expression of miR-34 family
members and overexpression of miR-34 caused the cell cycle
arrest at the G1 phase [10–16].
Here we report potential cell cycle regulating miRNAs during
the search of cancer related miRNAs in human lung cancer cells.
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6677In this study we revisit a set of genomic regions identified by Zhao et
al. that are amplified or deleted in human lung cancers [17]. During
the study, we found that miR-107 (MIMAT0000104) and miR-185
(MIMAT0000455) suppress proliferation in lung adenocarcinoma
celllinesandinducecell cyclearrestattheG1phaseofthecellcycle.
We attempted to characterize downstream target messenger RNAs
of these miRNAs by the use of microarray profiling with gene
ontology analyses and TargetScan predictions [18].
Results
Expression of miR-31, 107, and 185 in human tissue
collection including lung cancer tissue and cell lines
From the regions identified by Zhao et al. [17], we found 13 and
26 annotated miRNAs in the homozygously deleted and amplified
regions respectively (supplementary table S1). Because many of the
cancer related genes contribute to malignant transformation in
wide spectrum of cell types, we prioritized miRNAs that have been
implicated in other adult-onset human cancers. Then we chose
three miRNAs : miR-107, miR-185, and miR-31 (MI-
MAT0000089) [19–22]. We added the let-7a for cell growth
and cell cycle control because the miRNA can suppress cell growth
in the lung cancer cell lines [23] and induce cell cycle arrest in the
HepG2 cell line [7].
Using Taq-Man quantitative RT-PCR technology, we mea-
sured the expression of the four miRNAs in the human lung
cancer cell lines A549 and H1299 and across a panel of
commercially available RNAs from normal tissue and lung cancer
samples (Fig. 1). Most of the miRNAs showed relatively ubiquitous
expression among healthy tissues (Fig. 1). It is interesting that
expression of the analyzed miRNAs (miR-107, 185, and let-7a)
were lower in the lung tumor and lung cancer cell lines than in
normal lung. The miR-31 was highly expressed in the lung cancer
cell lines.
Growth suppression and cell cycle arrest by over-
expression of candidate miRNAs in human lung cancer
cell lines
The effect of these miRNAs on proliferation was tested by MTT
assay with pre-miRNA transfected H1299 and A549 cells.
Transfection of hsa-miR-107 and hsa-miR-185 dramatically
reduced cell proliferation in both cell lines (Fig. 2). In the case of
H1299 cells, the let-7a miRNA showed significantly reduced
proliferation while the effects were less obvious in A549 cells. The
extent of growth suppression of A549 by let-7a is similar to that of
reported [7]. The miR-31 showed slight suppression of cell growth
but the suppression levels were not statistically significant at many
time points for both of the cells (Fig. 2).
DNA content analysis by flow cytometry revealed transfection
of hsa-miR-107 and hsa-miR-185 induced a significant increase in
the percentage of cells at the G1 phase of the cell cycle, to similar
levels as a let-7a control while a scrambled negative control did not
(Fig. 3). We did not observe either any apparent increase of the
sub-G1 population in the flow cytometry or any apoptosis-related
morphological changes, such as nuclear blebbing and condensa-
tion, under the phase contrast microscope (data not shown). This
suggests that growth suppression induced by hsa-miR-107 and
hsa-miR-185 transfection was caused by induction of G1 arrest
rather than apoptosis.
Identification of candidate target mRNAs of the miRNAs
by gene profiling analysis
The microarray profiling was done to determine the global
changes in mRNA expression levels in H1299 cells transfected
with growth suppressive miRNAs compared to a negative control.
In the hsa-miR-107, hsa-miR-185 and hsa-let-7a transfected cells
there were 561, 646 and 812 transcripts down-regulated and 608,
698 and 949 upregulated by 1.5 fold or greater, respectively. Gene
Figure 1. Expression of candidate miRNAs in normal tissues and lung cancer. miRNA expression levels were measured by miRNA TaqMan
qRT-PCR in normal lung, brain, pituitary, liver and ovary tissues, a lung tumor sample and also in the lung tumor cell lines, H1299 and A549. The
vertical axis indicates the relative expression of each miRNA normalized with that of RNU44.
doi:10.1371/journal.pone.0006677.g001
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the transfectans. Table 1 lists the most significantly enriched GO
terms for the down-regulated genes with each miRNA. The top
five terms in genes down-regulated by hsa-miR-107 were all cell
cycle related (table 1). Down-regulated genes with the let-7a were
mainly involved in rRNA metabolism, ribosome biogenesis, and
the M phase of the cell cycle. Finally, the down-regulated genes
with hsa-miR-185 showed no enrichment for cell cycle related
terms, instead of the terms related to the development and
differentiation were prominent. In addition the 127 and 33 genes
commonly down-regulated and upregulated respectively by both
miRNAs showed no gene ontology enrichments, suggesting that
these miRNAs induce cell cycle arrest with different signaling
pathways (tables 2, 3, and data not shown).
We compared the miRNA target predictions with the
TargetScan software [18] for these miRNAs to the genes down-
regulated in our expression profiling datasets. For both conserved
and non-conserved sites, we found the median fold change of
Figure 2. Overexpression of miR-107 and miR-185 causes growth suppression and induces G1 cell cycle arrest. Growth suppression
effect of miRNA candidate transfections on H1299 (left panel) and A549 (right panel) as measured by MTT assay. The vertical axis indicates the relative
ratio of the A450 nm: that of day 0 of each cell as 1. Note miR-107 and miR-185 suppresses proliferation in both cell lines.
doi:10.1371/journal.pone.0006677.g002
Figure 3. Effect of miR-107, miR-185 and let-7a over-expression on cell cycle profile in H1299 cells. Histograms of DNA contents
obtained by FACS analysis are shown. The percentages of each cell cycle stages are shown in the inset of the histograms. There was no gate applied
to the events so that there was no obvious accumulation of sub-G1 populations in all the experiments.
doi:10.1371/journal.pone.0006677.g003
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PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6677Table 1. Gene ontology terms enriched of genes down-regulated by miR-107, miR-185 and let-7a transfection.
GO category GO terms (# of genes) # of genes affected P-value
mir107
GO:0022403 cell cycle phase (304) 135 7.66E-14
GO:0022402 cell cycle process (519) 203 1.58E-13
GO:0007049 cell cycle (635) 238 1.73E-13
GO:0000279 M phase (248) 114 1.82E-13
GO:0051301 cell division (197) 95 6.04E-13
GO:0000278 mitotic cell cycle (279) 119 6.71E-11
GO:0000087 M phase of mitotic cell cycle (203) 93 9.18E-11
GO:0007067 mitosis (201) 92 1.18E-10
GO:0006259 DNA metabolic process (665) 218 0.0000106
GO:0006260 DNA replication (190) 77 0.0000235
GO:0006974 response to DNA damage stimulus (283) 105 0.0000428
GO:0006281 DNA repair (232) 88 0.000126
GO:0007059 chromosome segregation (55) 28 0.00108
GO:0000070 mitotic sister chromatid segregation (26) 16 0.00341
GO:0006270 DNA replication initiation (26) 16 0.00341
GO:0000819 sister chromatid segregation (27) 16 0.00732
mir185
GO:0032501 multicellular organismal process (2482) 695 1.26E-14
GO:0007275 multicellular organismal development (1739) 496 4.76E-11
GO:0048513 organ development (900) 283 7.98E-11
GO:0048731 system development (1265) 376 7.98E-11
GO:0048856 anatomical structure development (1576) 453 8E-11
GO:0032502 developmental process (2503) 664 8.08E-09
GO:0009653 anatomical structure morphogenesis (831) 248 0.000000877
GO:0009888 tissue development (234) 88 0.000000914
GO:0030154 cell differentiation (1404) 387 0.00000199
GO:0048869 cellular developmental process (1404) 387 0.00000199
GO:0007154 cell communication (2838) 722 0.0000032
GO:0007166 cell surface receptor linked signal transduction (1061) 300 0.00000713
GO:0007165 signal transduction (2569) 651 0.0000395
GO:0009887 organ morphogenesis (301) 102 0.0000395
GO:0001568 blood vessel development (139) 54 0.000197
GO:0001944 vasculature development (140) 54 0.000252
GO:0008277 regulation of G-protein coupled receptor protein signaling pathway (26) 16 0.000365
GO:0048514 blood vessel morphogenesis (125) 49 0.000365
GO:0048646 anatomical structure formation (128) 50 0.000365
GO:0015031 protein transport (616) 85 0.000404
GO:0008104 protein localization (684) 98 0.00055
GO:0033036 macromolecule localization (722) 105 0.00055
GO:0009611 response to wounding (295) 96 0.000577
GO:0006412 translation (455) 58 0.000646
GO:0007186 G-protein coupled receptor protein signaling pathway (531) 157 0.000646
GO:0044237 cellular metabolic process (6365) 1257 0.000646
GO:0006952 defense response (350) 110 0.000684
GO:0045184 establishment of protein localization (650) 93 0.000684
GO:0048771 tissue remodeling (76) 33 0.000684
GO:0001501 skeletal development (163) 59 0.000703
let7a
GO:0042254 ribosome biogenesis (85) 60 2.32E-16
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detected in the arrays (Fig. 4). There is a trend for more strongly
predicted targets to be more down-regulated than weak predicted
targets. Similarly, the conserved targets tend to be more down-
regulated than all predicted targets (Fig. 4).
We then matched these computer-predicted targets to the genes
down-regulated more than 0.75 fold at the RNA level to narrow
down the potential targets of these miRNAs. We found many of
these potential targets were annotated with the terms ‘‘cell cycle’’
in Entrez Gene annotations (table 2) suggesting that these three
miRNAs may directly regulate the cell cycle progression through
these genes. Interestingly, in our hand, the let-7 did not suppress
the expression of the CDK6 (NM_001145306 ) mRNA, which is
suppressed by the overexpression of let-7 in the previous study [7].
Table 2. List of commonly downregulated cell cycle related
genes by transfection of different miRNAs.
entrez symbol Fold change in expression
mir-107 mir-185 let-7
SMG6 0.130749 0.126058 0.111471
FUNDC2 0.570185 0.523724 0.492232
MUC20 0.64695 0.499866 0.323235
BCL2L11 0.736578 0.41652 NS
CCNE1 0.376009 0.512158 NS
CDK6 0.565894 0.705571 NS
RASSF5 0.423999 0.44275 NS
RUNX3 0.653897 0.731732 NS
VEGFA 0.690304 0.6205 NS
XRCC3 0.723088 0.537486 NS
TUBGCP3 0.365103 0.607218 NS
TPD52 0.36629 0.639004 NS
RAB1B 0.470178 0.397512 NS
MAP9 0.502884 0.719742 NS
RAPGEF1 0.515269 0.726705 NS
CDK5R1 0.538231 0.638624 NS
NS: Not suppressed.
doi:10.1371/journal.pone.0006677.t002
Table 3. List of commonly downregulated oncogenes by
transfection of different miRNAs.
entrez symbol Fold change in expression
mir-107 mir-185 let-7
FUNDC2 0.5701851 0.5237243 0.49223238
MUC20 0.64695007 0.49986598 0.32323453
BCL2L11 0.73657805 0.41651997 NS
VEGFA 0.6903044 0.62050027 NS
TPD52 0.36629018 0.6390038 NS
RAB1B 0.47017783 0.3975123 NS
RAPGEF1 0.51526946 0.72670466 NS
PIM1 0.66107285 0.48559082 NS
RAB35 0.71937436 0.30117804 NS
HMGA2 NS 0.4689389 0.052681383
FGF5 NS 0.62565315 0.3222275
PATZ1 NS 0.6462347 0.5966134
CCND2 0.7438488 NS 0.523334
CBL 0.41297674 NS 0.4365899
RGPD5 0.63766026 NS 0.7261504
ABL2 0.7186717 NS 0.67202175
NS: Not suppressed.
doi:10.1371/journal.pone.0006677.t003
GO category GO terms (# of genes) # of genes affected P-value
GO:0022613 ribonucleoprotein complex biogenesis and assembly (177) 98 6.22E-15
GO:0006364 rRNA processing (60) 41 5.53E-10
GO:0010467 gene expression (2934) 929 7.63E-10
GO:0016072 rRNA metabolic process (63) 42 7.63E-10
GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolic process (3216) 991 0.000000141
GO:0006396 RNA processing (419) 167 0.000000191
GO:0016070 RNA metabolic process (2479) 774 0.00000174
GO:0043170 macromolecule metabolic process (5608) 1634 0.00000248
GO:0044237 cellular metabolic process (6395) 1830 0.0000105
GO:0044238 primary metabolic process (6396) 1834 0.000024
GO:0043283 biopolymer metabolic process (4287) 1256 0.000159
GO:0007154 cell communication (2838) 648 0.000212
GO:0006412 translation (455) 163 0.00124
GO:0044249 cellular biosynthetic process (860) 285 0.00124
GO:0032501 multicellular organismal process (2482) 570 0.00255
GO:0009451 RNA modification (31) 19 0.00499
GO:0006399 tRNA metabolic process (111) 49 0.00634
GO:0007267 cell-cell signaling (465) 85 0.00923
doi:10.1371/journal.pone.0006677.t001
Table 1. Cont.
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downregulated by these miRNAs.
From these lists and other list describing candidate miRNA
targets annotated with the terms cell cycle, lung cancer, oncogene
or tumor suppressor in Entrez Gene annotations (supplementary
table S2), we chose a subset of transcripts for validation by qRT-
PCR by the comparison with the target lists provided by
TargetScan [18] and PicTar [24] software (Fig. 5A). For miR-107,
we confirmed mRNA down-regulation of CCNE1 (NM_001238),
CDK6, CDCA4 (NM_017955.3), RAB1B (NM_030981.2) and CRKL
(NM_005207.3),andformiR-185,weconfirmeddown-regulation of
CCNE1, CDK6, AKT1 (NM_001014431.1), HMGA2 (NM_003483.4)
and CORO2B (NM_006091.3) (Fig. 5B). We note that both miR-107
and miR-185 transfection caused down-regulation of cyclin E1
(CCNE1) and cyclin dependent kinase 6 (CDK6) mRNA levels
although the suppression level of CDK6 by miR-185 is modest
(Fig. 5B).We then confirmed bywestern blotting that CDK6protein
levels are also down-regulated by miR-107, whereas CDK6
expression was relatively unchanged by miR-185 (Fig. 5C). Because
the suppression level of CDK6 mRNA expression by miR-185 is
verymodest,thesubsequent decreaseofCDK6proteinexpressionat
the timepoint of observation (24 hours aftertransfection) maybetoo
little to be observed the conventional immunoblottings.
Discussion
We happened to find that miR-107 and miR-185 can suppress
cell proliferation in two lung cancer cell lines and induced a G1
arrest of the cell cycle. The extent of growth suppression by these
miRNAs is similar to that by the tumor suppressive miRNA, let-7.
Gene expression profiling analysis with the transfection of these
miRNAs indicated that only miR-107 showed significant enrich-
ment of cell cycle regulators for the downstream effectors. On the
other hand, miR-185 did not significantly repress cell cycle
regulator as well as let-7, a known cell cycle regulating miRNA [6].
The miR-185, however, could suppress the mRNA expression of
cell cycle regulating genes such as CDK6 and AKT1.
The commonly regulated gene sets by all three growth
suppressive miRNAs are not so many and not so strongly related
to the cell cycle regulation(Table 2).These results suggested that the
three miRNAs regulate distinct cellular signaling pathways. Since
miRNA has a wide range of targets in a cell (i.e. less specific) and
since the extent of suppression of the target expression by miRNA is
generally moderate, the function of miRNAs should be considered
as the ‘‘fine tuning’’ of gene expression in mammalian cells [25].
The accumulation of these small regulatory effects may cause the
significant biological reactions in the cells [5].On the other hand, a
few potential target molecules such as CCNE1 and CDK6 may be
critical for cell cycle regulation by these miRNAs. For example,
reduction of CCNE1 with siRNA causes cell cycle arrest in liver
cancer cell lines [26]. In the case of CDK6, reduction of CDK6 by
siRNA caused prolonged S-phase in human embryonic stem cells
[27]. In general, the importanceof miRNA in cell cycle regulationis
quite reasonable because miRNAs are supposed to be keymolecules
for induction of cell differentiation, which accompanies with cell
cycle arrest in many cases.
In terms of miR-107, other evidence supports a role for this
miRNA in G1 arrest and growth suppression. miR-107 shares 7 of
the 8 bases of its seed sequence with the miR-16 family of
miRNAs, which induce G1 arrest by targeting multiple cyclins and
cell cycle regulators, including CDK6 which we confirmed as a
miR-107 target [28]. Furthermore, a previous study found that
synthetic inhibitors for miR-107 increase proliferation of A549
cells, but do not effect HeLa cells [29] suggesting miR-107 may
indeed play a lung specific role in reducing proliferation.
Interestingly, the miR-107 showed overexpressions in pancreatic
cancers suggesting this miRNA has some positive role in
pancreatic carcinogenesis [21]. On the other hand, during the
preparation of this manuscript, Lee et al. reported that demeth-
ylation and deacetylation treatments to human pancreatic cancer
Figure 4. Plot of median signal of TargetScan predicted targets at different thresholds. Target scan predictions were extracted for
miRNAs 185, 107 and let7a. Median expression signal is shown only for genes considered as detected by the Agilent software. Y-axis indicates the
median fold change for sets of predicted microRNA target genes at different thresholds, compared to all genes on the microarray (shown in black). In
all cases the median signal of predicted targets is lower than that observed if all probes are used. When the experiment is extended out to three days,
we observe less of an effect, suggesting direct targets are more affected within the first day.
doi:10.1371/journal.pone.0006677.g004
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overexpression of miR-107 suppressed cell growth and the
expression of the CDK6 in the human pancreatic cancer cell
lines [30]. The latter study is compatible to our data in terms of
CDK6 as a candidate downstream target of miR-107. It is
interesting whether this miRNA did have any specific cellular
functions in the cells rather than cell cycle regulation. Safdar et al.
suggested that miR-107 has been induced in exercised mice
quadriceps muscles [31]. According to the review by Wilfred et al.,
the miR-107 and its paralog, miR-103, may function in the
regulation of cellular metabolism [32]. It may be interesting
possibility that these miRNAs regulate the fundamental cellular
functions such as metabolism or cell cycle progression rather than
the specification of cell differentiation.
The mechanism of cell cycle arrest by miR-185 is not clear. The
number of cell cycle regulators in the downstream suppressed
genes is much lower by miR-185 than by miR-107. One group of
scientists suggested that this miRNA is overexpressed in bladder
cancer [20]. In the other paper, Choong reported that miR-185
have strong positive correlation to the appearance of erythroid
surface antigens (CD71, CD36, and CD235a) in human umbilical
cord blood cells stimulated with growth factors and induced
erythroid differentiation [33]. Generally speaking, the induction of
cell differentiation usually couples with the suppression of cell cycle
progression. Considering the miRNA functions in other metazo-
ans, many of the miRNAs inducible with cell differentiation might
have some cell cycle suppressive functions. The miRNA should
have other biological functions in different cell types. It is therefore
interesting to investigate whether miR-185 has any differentiating
functions in lung cancer cells. Another important question is that
miR-185 showed growth suppressive functions (figures 2, 3) and
decrease of expression in lung cancer cells (figure 1) even though
the miRNA is localized in a chromosomal region amplified in two
lung cancer cell lines ([17] and supplementary table S1). These
results are counter-intuitive. It is possible, however, that the tumor
suppressors can be localized in a region showing chromosomal
amplification in tumor cells. One example is a potential tumor
suppressive gene, GSDMA(NM_178171.4) [34], is localized in a
chromosomal region amplified in gastric cancer cells [35]. This
gene is downregulated in the human gastric cancers even though
the gene showed amplification in tumor cells [35]. In the case of
the miR-185, epigenetic silencing of the miRNA might occur prior
to the gene amplification of the chromosome 22q21.1 region.
Further investigation clearly needs to address these questions
thoroughly.
Finally, we report that new candidate miRNAs which can
regulate cell cycle progression in human non-small cell lung cancer
cell lines. It is still an open question that whether any somatic
Figure 5. Confirmation of mRNA down-regulation by qRTPCR for predicted targets. A) Representative nucleotide sequence matches
between possible target genes and miRNAs. The numbers in parenthesis indicates the positions of target nucleotides from the stop codon. Only
matched nucleotides with miRNA seed sequences are indicated with the vertical lines. B) The quantitative RT-PCR analyses of potential targets of
miR-107 (CCNE1, CDK6, CDCA4, RAB1B and CRKL) and miR-185 (CCNE1, CDK6, AKT1, HMGA2, CORO2B) are shown. The vertical axis indicates the
relative expression ratio of each gene normalized with that of GAPDH. C) Western Blot showing down-regulation of CDK6 protein by miR-107.
doi:10.1371/journal.pone.0006677.g005
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human lung cancer or any other malignant tumors. Further
characterization of the genomic loci of these miRNAs is necessary
to make the issue clear.
Methods
Extraction of miRNA position
Annotated miRNA loci were extracted from regions of
chromosomal gain and loss identified by Zhao et al. [17] in a
large panel of human lung carcinomas using SNP arrays. The
Hg16 co-ordinates were converted to their Hg18 using equivalents
using the UCSC Lift-Over tool (http://genome.ucsc.edu).
Cell lines
Human lung cancer cell lines, H1299 and A549, were
purchased from ATCC. The cell lines were grown in DMEM
containing 10% heat-inactivated fetal bovine serum, 100 mg/ml of
penicillin/streptomycin and 292 mg/ml of L-glutamine (Invitro-
gen, Carlesbad, CA, USA).
RNA preparations and quantification of RNAs using real-
time PCR
All the realtime PCR was performed with StepOnePlus
Realtime PCR system (Applied Biosystems, Foster City, CA,
USA) in quadruplicate. Total RNA was extracted from H1299
and A549 cells with the mirVana miRNA isolation kit (Ambion,
Austin, TX, USA). Total RNAs of human tissues were purchased
from BioChain Institute, Inc. (Hayward, CA, USA; Catalog
numbers: R1234152-50, R1235152-50, R1234035-50, R1234068-
10, R1234149-50, R1234183-50). For quantification of miRNAs,
100 ng of total RNA was analyzed with TaqMan MicroRNA
Reverse Transcription (RT) Kit (Applied Biosystems) with RNU44
as loading control. For quantification of mRNAs, 500 ng of total
RNA was reverse-transcribed using the PrimeScript II RT
Enzyme (Takara Bio, Inc., Shiga, Japan) and PCR was performed
with SYBR premix Ex Taq (Perfect Real Time: Takara Bio, Inc.)
with GAPDH as loading control. All the real-time PCR analysis
were done in triplicate.
miRNA transfection
Synthetic pre-miRNAs and nonspecific negative control (miR-
IDIAN microRNA Mimic Negative Control#1) were purchased
from Dharmacon, Inc. (Lafayette, CO, USA). The pre-miRNAs
were transfected at a final concentration of 10 nM with
Lipofectamine2000 (Invitrogen), and medium changed 24 hours
after transfection.
Cell growth measurement
Cells were plated in 96-well plates and incubated at 37uCi na
5% CO2 incubator. Cell viability was evaluated by MTT assay
using the Cell counting kit-8 (DOJINDO, Kumamoto, Japan),
according to the manufacturer’s protocol. After 1 hour incubation
with the media containing tetrazolium compound, the absorbance
at 450 nm was detected for 0.1 sec with Arvo MX 1420 (Perkin
Elmer, Waltham, MA, USA).
Cell cycle analysis
Cells were harvested after 72 hours and fixed in 70% ice cold
ethanol and followed by RNAse A treatment, stained with 50 mg/
ml of Propidium Iodide for DNA content analysis by flow
cytometry analysis on a FACS Calibur system (Becton Dickinson,
Franklin, NJ, USA). The data were collected and processed using
the FlowJo FACS analysis software (Tree Star, Inc., Ashland, OR,
USA).
Expression profiling using Agilent Gene expression array
The cRNA probe was generated from total RNA (500 ng) with
the Low RNA Input linear amplification & Labeling kit (Agilent
Technologies, Santa Clara, CA, USA). Cy3-labeled cRNA
(1.65 mg) was then fragmented and relative expression was
measured by hybridization to 4644K whole human oligo
microarray (Agilent). Feature Extraction ver. 9.1 software (Agilent)
was used to analyze the image of microarray. The microarray
analyses were performed in duplicate. All microarray data
reported in the manuscript is described in accordance with
MIAME guidelines and the data has been deposited in CIBEX
(Center for Information Biology gene Expression) database [36] at
Center for Information Biology and DNA Data Bank of Japan
(DDBJ), National Institute of Genetics (Mishima, Japan). The
accession number for the dataset is CBX79.
Microarray and Gene ontology analysis
Microarray data was visualized and normalized using Gene-
spring GX 7.3 software (Agilent). Values below 0.01 were set to
0.01. For each chip each measurement was divided by the 50th
percentile of all measurements for that chip. Then for each probe
the measurements were normalized to the negative control
measurements. Because of the limitation of the resources, the
statistic p-value may not be applicable criteria for gene selection of
our dataset. Hence, for gene ontology analysis, differentially
expressed genes were defined as $1.5 fold up or down relative to
the negative control on the corresponding day. Gene Ontology
term enrichment in up and down regulated gene sets were assessed
using the GOstat web tool [37]. The GOstat web tool provides a
p-value on whether the gene list provided is significantly enriched
for genes annotated with a particular Gene Ontology. This is
calculated based upon how many genes in the gene set are
annotated with the given ontology, and how many genes on the
entire microarray (the background) are annotated with the same
ontology. We defined the background as the set of genes detected
in at least one of the array experiments.
Antibodies and immunoblotting analysis
Antibodies to the a-tubulin (Sigma) and CDK6 (Santa-Cruz
Biotechnology, Santa-Cruz, CA) were used. Cultured cells
(5.0610 ˆ5 cells/well) were grown on 6-well plate wells and
transfected with miRNAs. 24 hours after the transfection, the
cells were lysed and subjected to SDS-polyacrylamide gel
electrophoresis. The separated proteins were transferred onto
Immobilon membrane (Millipore, Billerica, MA) by electroblot-
ting. Immune complexes were detected by enhanced chemilumi-
nescence (Perkin Elmer) and visualized with LAS 3000 image
analyzer (Fuji film, Tokyo, Japan).
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